Radboudumc researchers used metabolomics to study cerebrospinal fluid (CSF) samples from tuberculous meningitis patients in Vietnam and Indonesia, with long-standing collaborators from Bandung and ...

Tuberculous Meningitis (TBM) is the most severe form of extrapulmonary tuberculosis, posing a critical global health challenge. This devastating central ...

Tuberculosis meningitis (TBM) is a severe infection caused by Mycobacterium tuberculosis that spreads to the membranes surrounding the brain and spinal cord. Without prompt treatment, it can lead to ...

Each year, 11 million people worldwide develop tuberculosis, and about 1.4 million die from it. Meningitis occurs in 1–2% of patients and is the most severe complication of tuberculosis, arising when ...

Adjunctive glucocorticoids are widely used to treat human immunodeficiency virus (HIV)–associated tuberculous meningitis despite limited data supporting their safety and efficacy. We conducted a ...

A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The Improved Management with ...

Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervous ...

New drugs may be needed to fight the deadliest form of tuberculosis, because it may no longer respond to current treatments. An animal study by Johns Hopkins University researchers found that an ...

High-dose rifampin — 35 mg/kg daily — administered for 8 weeks showed no reduction in mortality rate compared with standard-dose rifampin — 10 mg/kg daily — in patients with tuberculous meningitis but ...

A Johns Hopkins Children's Center-led study in animals suggests that high doses of a widely used antibiotic called rifampin may safely treat and reduce the duration of treatment for the deadliest form ...